28 February 2024

TruSpine Technologies plc

("TruSpine" or the "Company")

Director Appointments

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused on the development of its pioneering "screwless," spinal (vertebral) stabilisation systems announces that, further to the announcement on 27 November 2023, Victoria Sena and Samuel Ogunsalu have been appointed as Non-Executive Directors of the Company. In addition the Company has appointed Geoffrey Miller as Non-executive Chairman.

Victoria Sena

Victoria Sena founded Cherrybank Consulting Limited in 2019 to assist clients in the areas of governance, operations, risk, and compliance. Previously Victoria spent eight years at the Bank of England in the authorisations, banking, and insurance divisions, and completed a secondment to the Treasury Committee of the House of Commons. After moving to the private sector Victoria served as a Group Risk Manager for an international insurance group, before becoming Chief Operating Officer of a boutique investment manager where she was an FCA Approved Person. She is a Chartered Member of the Chartered Institute of Securities and Investments and holds degrees from Oxford University and the London School of Economics and Political Science.

Save as set out below, no further information regarding Victoria Sena is required to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.

Victoria Lisa Nadine Sena (aged 35) has held the following current and former directorships within the past five years:

Victoria Sena holds no ordinary shares, options or warrants over ordinary shares in the Company.

Samuel Ogunsalu

Samuel Ogunsalu has over 20 years' experience in technology commercialisation, licensing, and business development. He has executed a wide number of transactions ranging from negotiating licences and M&As, to transformational technology partnerships with companies such as Merck, GSK, Pharmacia (merged with Pfizer) and Abbott (now AbbVie) as well as helping to establish preclinical research programmes with a number of industrial partners and set up joint ventures, start-ups, and spinout companies to develop novel technologies. Samuel was previously Chief Business Officer & Director of an oncology company and Chief Commercial Officer of an AIM quoted biotech company. Prior to that he has held a number of positions across technology business units connected with Queen Mary College, London, as well as other roles in which he has advised private and listed companies in both the UK and the USA. He started his professional career as a pilot plant engineer at Imperial College, London, followed by scientific research at University College London, before moving into business & commercial development. Samuel holds a BSc in Microbiology from the University of Wales, and an MSc in Biochemical Engineering from UCL.

Save as set out below, no further information regarding Samuel Ogunsalu is required to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.

Samuel Olawole Ogunsalu (aged 57) has held the following current and former directorships within the past five years:

Mr. Ogunsalu was a director of Viratis Limited. A liquidator was appointed on 23 February 2010 to undertake a voluntary liquidation. The company was dissolved on 9 June 2011 with all creditors settled and a distribution to shareholders.

Samuel Ogunsalu holds 200,000 ordinary shares in the Company. Sam hold no options or warrants over ordinary shares in the Company.

Geoffrey Miller

Mr Miller currently serves as the co-Founder of Afaafa Ltd, his venture capital company that he shares with his spouse since 2013. Additionally, he serves as the Chairman of Conviction Life Sciences Company Ltd since 2022; was Chairman at MJ Hudson PLC from 2022-2023, having been a Non-Executive Director from 2019-2021; Chairman at Globalworth Real Estate Investments Ltd from 2013-2021; Chief Executive Officer at GLI Finance Ltd from 2009-2015, Chairman at Hastings Insurance Group Ltd from 2012-2014 and Aurora Russia Ltd from 2011-2013. Prior to this, Mr Miller was Head of Research Marketing at Troika Dialog in Moscow from 2008-2009, Director, Research at Bridgewell Ltd from 2003-2007 and a Fund Manager at Exeter Asset Management from 1999-2003 having served as an Investment Director at Wise Speke Limited, subsequently Brewin Dolphin Securities, from 1992-1999.

Save as set out below, no further information regarding Geoffrey Miller is required to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.

Geoffrey Richard Miller (aged 57) has held the following current and former directorships within the past five years:

Mr. Miller was a director of Funding Knight Holdings Limited. An administrator was appointed on 28 June 2016 and on 15 August 2016 a liquidator was appointed to undertake a creditors voluntary liquidation. The company was dissolved on 27 June 2018 with all creditors settled and a distribution to shareholders.

Mr. Miller is a director of MJ Hudson Group PLC and of MJ Hudson Group Holdings Limited. In August 2023, following the sale of the operations of MJ Hudson Group PLC, both companies were put into a creditors voluntary liquidation which is ongoing.

Geoffrey Miller holds 1,800,000 ordinary shares in the Company through his pension. Geoffrey holds no options or warrants over ordinary shares in the Company.

There is no further information to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Enquiries:

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.